237 related articles for article (PubMed ID: 23600720)
1. Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles.
Löw K; Aebischer P; Schneider BL
Hum Gene Ther; 2013 Jun; 24(6):613-29. PubMed ID: 23600720
[TBL] [Abstract][Full Text] [Related]
2. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
3. Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.
Hammond SL; Leek AN; Richman EH; Tjalkens RB
PLoS One; 2017; 12(12):e0188830. PubMed ID: 29244806
[TBL] [Abstract][Full Text] [Related]
4. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
Mandel RJ; Spratt SK; Snyder RO; Leff SE
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14083-8. PubMed ID: 9391156
[TBL] [Abstract][Full Text] [Related]
5. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
6. Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.
Paterna JC; Feldon J; Büeler H
J Virol; 2004 Jul; 78(13):6808-17. PubMed ID: 15194756
[TBL] [Abstract][Full Text] [Related]
7. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
[TBL] [Abstract][Full Text] [Related]
8. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
9. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
10. Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.
Hurtado-Lorenzo A; Millan E; Gonzalez-Nicolini V; Suwelack D; Castro MG; Lowenstein PR
Mol Ther; 2004 Sep; 10(3):507-24. PubMed ID: 15336651
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain.
San Sebastian W; Samaranch L; Heller G; Kells AP; Bringas J; Pivirotto P; Forsayeth J; Bankiewicz KS
Gene Ther; 2013 Dec; 20(12):1178-83. PubMed ID: 24067867
[TBL] [Abstract][Full Text] [Related]
12. Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants.
Benskey MJ; Kuhn NC; Galligan JJ; Garcia J; Boye SE; Hauswirth WW; Mueller C; Boye SL; Manfredsson FP
Mol Ther; 2015 Mar; 23(3):488-500. PubMed ID: 25592336
[TBL] [Abstract][Full Text] [Related]
13. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat.
Dass B; Iravani MM; Huang C; Barsoum J; Engber TM; Galdes A; Jenner P
J Neural Transm (Vienna); 2005 Jun; 112(6):763-78. PubMed ID: 15586304
[TBL] [Abstract][Full Text] [Related]
14. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.
Chung CY; Koprich JB; Siddiqi H; Isacson O
J Neurosci; 2009 Mar; 29(11):3365-73. PubMed ID: 19295143
[TBL] [Abstract][Full Text] [Related]
15. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease.
Xue YQ; Ma BF; Zhao LR; Tatom JB; Li B; Jiang LX; Klein RL; Duan WM
Gene Ther; 2010 Jan; 17(1):83-94. PubMed ID: 19727138
[TBL] [Abstract][Full Text] [Related]
16. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.
Liang ZQ; Li YL; Zhao XL; Han R; Wang XX; Wang Y; Chase TN; Bennett MC; Qin ZH
Brain Res; 2007 May; 1145():190-203. PubMed ID: 17368433
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
19. Injury induced c-Jun expression and phosphorylation in the dopaminergic nigral neurons of the rat: correlation with neuronal death and modulation by glial-cell-line-derived neurotrophic factor.
Vaudano E; Rosenblad C; Björklund A
Eur J Neurosci; 2001 Jan; 13(1):1-14. PubMed ID: 11134999
[TBL] [Abstract][Full Text] [Related]
20. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.
Burger C; Gorbatyuk OS; Velardo MJ; Peden CS; Williams P; Zolotukhin S; Reier PJ; Mandel RJ; Muzyczka N
Mol Ther; 2004 Aug; 10(2):302-17. PubMed ID: 15294177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
